These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

897 related articles for article (PubMed ID: 33027976)

  • 1. The CNS and the Brain Tumor Microenvironment: Implications for Glioblastoma Immunotherapy.
    Desland FA; Hormigo A
    Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33027976
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current approaches in glioblastoma multiforme immunotherapy.
    Aghajani M; Jalilzadeh N; Aghebati-Maleki A; Yari A; Tabnak P; Mardi A; Saeedi H; Aghebati-Maleki L; Baradaran B
    Clin Transl Oncol; 2024 Jul; 26(7):1584-1612. PubMed ID: 38512448
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhancing Glioblastoma Immunotherapy with Integrated Chimeric Antigen Receptor T Cells through the Re-Education of Tumor-Associated Microglia and Macrophages.
    Zhu N; Chen S; Jin Y; Wang M; Fang L; Xue L; Hua D; Zhang Z; Jia M; Hao M; Zhang C
    ACS Nano; 2024 Apr; 18(17):11165-11182. PubMed ID: 38626338
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune Microenvironment in Glioblastoma Subtypes.
    Chen Z; Hambardzumyan D
    Front Immunol; 2018; 9():1004. PubMed ID: 29867979
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Local Targeting of NAD
    Li M; Kirtane AR; Kiyokawa J; Nagashima H; Lopes A; Tirmizi ZA; Lee CK; Traverso G; Cahill DP; Wakimoto H
    Cancer Res; 2020 Nov; 80(22):5024-5034. PubMed ID: 32998997
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emerging immunotherapies for glioblastoma.
    Desai R; Suryadevara CM; Batich KA; Farber SH; Sanchez-Perez L; Sampson JH
    Expert Opin Emerg Drugs; 2016 Jun; 21(2):133-45. PubMed ID: 27223671
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular Heterogeneity and Immunosuppressive Microenvironment in Glioblastoma.
    DeCordova S; Shastri A; Tsolaki AG; Yasmin H; Klein L; Singh SK; Kishore U
    Front Immunol; 2020; 11():1402. PubMed ID: 32765498
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Developing immunotherapeutic strategies to target brain tumors.
    Lieberman NA; Moyes KW; Crane CA
    Expert Rev Anticancer Ther; 2016 Jul; 16(7):775-88. PubMed ID: 27253692
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune Escape in Glioblastoma Multiforme and the Adaptation of Immunotherapies for Treatment.
    Pearson JRD; Cuzzubbo S; McArthur S; Durrant LG; Adhikaree J; Tinsley CJ; Pockley AG; McArdle SEB
    Front Immunol; 2020; 11():582106. PubMed ID: 33178210
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The immunosuppressive microenvironment and immunotherapy in human glioblastoma.
    Zhang X; Zhao L; Zhang H; Zhang Y; Ju H; Wang X; Ren H; Zhu X; Dong Y
    Front Immunol; 2022; 13():1003651. PubMed ID: 36466873
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Different T-cell subsets in glioblastoma multiforme and targeted immunotherapy.
    Wang H; Zhou H; Xu J; Lu Y; Ji X; Yao Y; Chao H; Zhang J; Zhang X; Yao S; Wu Y; Wan J
    Cancer Lett; 2021 Jan; 496():134-143. PubMed ID: 33022290
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human macrophages engineered to secrete a bispecific T cell engager support antigen-dependent T cell responses to glioblastoma.
    Gardell JL; Matsumoto LR; Chinn H; DeGolier KR; Kreuser SA; Prieskorn B; Balcaitis S; Davis A; Ellenbogen RG; Crane CA
    J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33122397
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advances in Nanotechnology-Based Immunotherapy for Glioblastoma.
    Tang L; Zhang M; Liu C
    Front Immunol; 2022; 13():882257. PubMed ID: 35651605
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunotherapy as a New Therapeutic Approach for Brain and Spinal Cord Tumors.
    Medikonda R; Pant A; Lim M
    Adv Exp Med Biol; 2023; 1394():73-84. PubMed ID: 36587382
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination immunotherapy strategies for glioblastoma.
    Chan HY; Choi J; Jackson C; Lim M
    J Neurooncol; 2021 Feb; 151(3):375-391. PubMed ID: 33611705
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypoxia within the glioblastoma tumor microenvironment: a master saboteur of novel treatments.
    Feldman L
    Front Immunol; 2024; 15():1384249. PubMed ID: 38994360
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Understanding the glioblastoma immune microenvironment as basis for the development of new immunotherapeutic strategies.
    Pombo Antunes AR; Scheyltjens I; Duerinck J; Neyns B; Movahedi K; Van Ginderachter JA
    Elife; 2020 Feb; 9():. PubMed ID: 32014107
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current Immunotherapies for Glioblastoma Multiforme.
    Huang B; Li X; Li Y; Zhang J; Zong Z; Zhang H
    Front Immunol; 2020; 11():603911. PubMed ID: 33767690
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Challenges in immunotherapy presented by the glioblastoma multiforme microenvironment.
    Jackson C; Ruzevick J; Phallen J; Belcaid Z; Lim M
    Clin Dev Immunol; 2011; 2011():732413. PubMed ID: 22190972
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD70 as an actionable immunotherapeutic target in recurrent glioblastoma and its microenvironment.
    Seyfrid M; Maich WT; Shaikh VM; Tatari N; Upreti D; Piyasena D; Subapanditha M; Savage N; McKenna D; Mikolajewicz N; Han H; Chokshi C; Kuhlmann L; Khoo A; Salim SK; Archibong-Bassey B; Gwynne W; Brown K; Murtaza N; Bakhshinyan D; Vora P; Venugopal C; Moffat J; Kislinger T; Singh S
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35017149
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 45.